Nordic Business Report-November 30, 2006-Novo Nordisk A/S expands US diabetes care sales force from 1,200 to 1,900 (C)1994-2006 M2 COMMUNICATIONS LTD http://www.m2.com Danish pharmaceutical company Novo Nordisk A/S (NYSE: NVO) announced on Thursday (30 November) plans to expand its diabetes care sales force in the US from the current 1,200 to approximately 1,900. The expansion of the sales force will be effected during the first half of 2007, and will further strengthen Novo Nordisks position in the US insulin market. "So many people with diabetes are still not in acceptable glycaemic control. That is why we are very pleased to announce the significant field force expansion in the US market which will support our complete portfolio of insulin analogues as well as our leading insulin injection device, FlexPen," said Marton Soeters, President of Novo Nordisk. "The expansion will prepare our organisation for future launches of additional innovative diabetes products that we currently have in clinical development," Soeters added. Novo Nordisk, headquartered in Copenhagen in Denmark, has the worlds broadest diabetes product portfolio. The company has over 23,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk is listed on the Nordic Exchange in Copenhagen, and on the NYSE. ((Comments on this story may be sent to [email protected]))